Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas

被引：0
|
作者：
Ramanathan, Ramesh K.
Von Hoff, Daniel D.
Moore, Malcolm J.
Teixeira, Luis
Siena, Salvatore
Tabernero, Josep
Goldstein, David
Wei, Xinyu
Lu, Brian
机构：
[1] Virginia G Piper Canc Ctr, Translat Genom Res Inst, Scottsdale, AZ USA
[2] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Hop St Antoine, F-75571 Paris, France
[5] Osped Niguarda Ca Granda, Falck Div Med Oncol, Milan, Italy
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] Prince Wales Hosp, Sydney, NSW, Australia
[8] Celgene Corp, Summit, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.254
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
254
引用
收藏
页数：1
相关论文
共 42 条
  • [11] Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.
    Kunzmann, Volker
    Ramanathan, Ramesh K.
    Goldstein, David
    Penenberg, Darryl Neil
    Ferrara, Stefano
    Lu, Brian
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [12] Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates
    Von Hoff, Daniel D.
    Ervin, Thomas J.
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Moore, Malcolm J.
    Seay, Thomas E.
    Tjulandin, Sergei
    Ma, Wen Wee
    Saleh, Mansoor N.
    Harris, Marion
    Reni, Michele
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Hidalgo, Manuel
    Van Cutsem, Eric
    Goldstein, David
    Wei, Xinyu
    Iglesias, Jose Luis
    Renschler, Markus Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [13] SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study
    Von Hoff, D. D.
    Ramanathan, R.
    Borad, M.
    Laheru, D.
    Smith, L.
    Wood, T.
    Korn, R.
    Desai, N.
    Iglesias, J.
    Hidalgo, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [14] nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
    Tehfe, Mustapha
    Dowden, Scot
    Kennecke, Hagen
    El-Maraghi, Robert
    Lesperance, Bernard
    Couture, Felix
    Letourneau, Richard
    Liu, Helen
    Romano, Alfredo
    ADVANCES IN THERAPY, 2016, 33 (05) : 747 - 759
  • [15] nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
    Mustapha Tehfe
    Scot Dowden
    Hagen Kennecke
    Robert El-Maraghi
    Bernard Lesperance
    Felix Couture
    Richard Letourneau
    Helen Liu
    Alfredo Romano
    Advances in Therapy, 2016, 33 : 747 - 759
  • [16] Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study
    Yu, X.
    Shen, L.
    Hao, J.
    Wang, L.
    Pan, H.
    Han, G.
    Xu, J.
    Zhang, Y.
    Yang, S.
    Ying, J.
    Li, M.
    Begic, D.
    Lu, B.
    Xu, R.
    ANNALS OF ONCOLOGY, 2015, 26 : 66 - 67
  • [17] Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns
    Sahai, Vaibhav
    Tabernero, Josep
    Van Cutsem, Eric
    Reni, Michele
    Tempero, Margaret A.
    O'Reilly, Eileen Mary
    Berlin, Jordan
    Riess, Hanno
    Goldstein, David
    Li, Mingyu
    Lu, Brian
    Ferrara, Stefano
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [18] Efficacy and safety of nab-Paclitaxel (nab-P) plus gemcitabine (Gem) vs gem alone in patients (Pts) with metastatic pancreatic cancer (MPC) treated to progressive disease (PD) in the phase III MPACT trial
    Vogel, A.
    Penenberg, D.
    McGovern, D.
    Romano, A.
    Michael, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S455 - S455
  • [19] APACT: Phase III, Multicenter, International, Open-Label, Randomized Trial of Adjuvant nab-Paclitaxel Plus Gemcitabine (nab-P/G) Versus Gemcitabine (G) for Surgically Resected Pancreatic Adenocarcinoma
    Ko, A.
    Reni, M.
    Riess, H.
    Pelzer, U.
    O'Reilly, E. M.
    Winter, J.
    Oh, D. Y.
    Li, C. P.
    Tortora, G.
    Chang, H. M.
    Lopez, C. D.
    Tabernero, J.
    Van Cutsem, E.
    Philip, P.
    Goldstein, D.
    Berlin, J. D.
    Ferrara, S.
    Li, M.
    Lu, B.
    Romano, A.
    Marks, H.
    Biankin, A.
    Tempero, M. A.
    PANCREAS, 2019, 48 (10) : 1464 - 1464
  • [20] CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).
    Chiorean, E. Gabriela
    Von Hoff, Daniel D.
    Ervin, Thomas J.
    Arena, Francis P.
    Infante, Jeffrey R.
    Bathini, Venu Gopal
    Wood, Tina Evans
    Mainwaring, Paul N.
    Muldoon, Robert T.
    Clingan, Philip R.
    Kunzmann, Volker
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Goldstein, David
    Ko, Amy
    Lu, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345